The The Drug Cell consortium, led by the French Blood Establishment (EFS), GPI, MGA Technologies, and the AFM-Téléthon Stem Cell Research Center, has secured a record-breaking €152 million funding from the European Union.
The goal: to build a modular and scalable cell therapy manufacturing plant in France by 2031.
Bringing together academic and industrial leaders, including Carroucell and EVerZom, this initiative aims to establish a sovereign European production capability, a field still largely dominated by the U.S. and Asia.
As Hervé de Malliard, CEO of MGA Technologies, states: “Our goal is to democratize access to these costly treatments by automating processes and making production viable in Europe.”
A significant leap forward for innovation and European health independence!
In the Same Category
Chronicles of a small industrialist who dreams of re-enchanting France – Episode 65
Chronicles of a small industrialist dreaming of re-enchanting France - Episode 65: Unity is strength.Last Wednesday, we brought a collective together. It was important. Everyone around us who understood that only collective intelligence can make us shine again. For...
Maison MGA boosts biotechnology in Mably: opening of a state-of-the-art cleanroom
On 29 April 2026, Maison MGA reached a key milestone for French industrial sovereignty by inaugurating its new facilities in Mably. As part of the event ‘Building the Healthcare Industry of the Future’, we officially opened a state-of-the-art cleanroom dedicated to...